Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05392881 · ClinicalTrials.gov registry record
Interstitial Lung Disease Research Unit Biobank
A clinical trial of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT05392881 is a study of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 1,000 participants, above the 732-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (37% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05392881, a study of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
Conditions Studied
Study Locations (1)
Kansas
- The University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2021-08-09 |
| Est. Completion | 2032-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05392881
The ClinicalTrials.gov registry entry for NCT05392881 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 732-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (37% higher). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT05392881 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT05392881 about?
NCT05392881 is a clinical study titled "Interstitial Lung Disease Research Unit Biobank". Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
What is the current status of trial NCT05392881?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2021-08-09. Estimated completion is 2032-03-01.
What conditions does trial NCT05392881 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Fibrosis, Sarcoidosis, Hypersensitivity Pneumonitis.
Who is sponsoring clinical trial NCT05392881?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05392881 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.